NVST Envista Holdings Corporation
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products, as well as provides DTX Studio Clinic, a software package offered with its imaging products. This segment offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.…
Industry Peers
Medical Instruments & SuppliesKey Statistics
About Envista Holdings (NYSE: NVST)
›
Envista Holdings (NYSE: NVST) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 12,000 employees.
The shares were at 23.27 USD on 19 November 2026, up 19.9% over 52 weeks. Its 52-week range is 18.77 USD to 30.42 USD: the price is 23.5% below the high and 24.0% above the low.
At a market capitalisation of 3.73B USD, it trades at 6.0 times trailing earnings and 13.9 times forward earnings. The median trailing P/E of its 19 largest Medical Instruments & Supplies peers is 49.2, a discount of 88% for NVST.
Envista Holdings reports return on equity of 1.5%, an operating margin of 10.6% and revenue up 3.2% year over year.
Its debt exceeds its cash by 428.70M USD, a debt-to-equity ratio of 0.51. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 13 analysts cover the stock, with an average rating of Buy; their mean price target of 28.92 USD is 24.3% above the current price. The next earnings report is expected on 3 February 2027.